Things are looking up for biotech and health device startups wanting to cash in on VC dollars or go public this year. According to Silicon Valley Bank’s latest report on healthcare investments and exits, a conservative 2016 has set 2017 up for a hearty boom.
Though biopharma M&A activity declined slightly last year and IPOs declined more than 30 percent, according to the report… Read More
from TechCrunch